A Trial to Evaluate the Effect of Low Dose Temozolomide (TMZ) for 2 Weeks on Brain Tumor O-6-Methylguanine-DNA Methyltransferase (MGMT) Activity in Patients With Gliomas.
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2017
At a glance
- Drugs Temozolomide (Primary)
- Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
- Focus Therapeutic Use
- Sponsors Schering-Plough
- 31 Aug 2018 Biomarkers information updated
- 27 Jan 2012 Actual end date changed from Jan 2011 to Feb 2011 as reported by ClinicalTrials.gov.
- 02 Feb 2011 Planned end date changed from 1 Mar 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.